{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:08:52Z","timestamp":1790791732705,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,2,8]],"date-time":"2013-02-08T00:00:00Z","timestamp":1360281600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s11011-013-9383-5","type":"journal-article","created":{"date-parts":[[2013,2,7]],"date-time":"2013-02-07T00:03:43Z","timestamp":1360195423000},"page":"307-312","source":"Crossref","is-referenced-by-count":96,"title":["Antibiotics for the treatment of hepatic encephalopathy"],"prefix":"10.1007","volume":"28","author":[{"given":"Kavish R.","family":"Patidar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmohan S.","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,8]]},"reference":[{"issue":"5","key":"9383_CR1","first-page":"11","volume":"149","author":"J Alcorn","year":"2008","unstructured":"Alcorn J (2008) Review: rifaximin is equally or more effective than other antibiotics and lactulose for hepatic encephalopathy. ACP J Club 149(5):11","journal-title":"ACP J Club"},{"key":"9383_CR2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/BF01072921","volume":"23","author":"CE Atterbury","year":"1978","unstructured":"Atterbury CE, Maddrey WC, Conn HO (1978) Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy: a controlled, double-blind clinical trial. Am J Dig Dis 23:398\u2013406","journal-title":"Am J Dig Dis"},{"issue":"5","key":"9383_CR3","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2036.2009.04211.x","volume":"31","author":"JS Bajaj","year":"2010","unstructured":"Bajaj JS (2010) Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther 31(5):537\u2013547","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"9383_CR4","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/hep.23866","volume":"52","author":"JS Bajaj","year":"2010","unstructured":"Bajaj JS, Riggio O (2010) Drug therapy: rifaximin. Hepatology 52(4):1484\u20131488","journal-title":"Hepatology"},{"issue":"2","key":"9383_CR5","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1053\/j.gastro.2010.08.061","volume":"140","author":"JS Bajaj","year":"2011","unstructured":"Bajaj JS, Heuman DM, Wade JB, Gibson DP, Saeian K, Wegelin JA, Hafeezullah M, Bell DE, Sterling RK, Stravitz RT, Fuchs M, Luketic V, Sanyal AJ (2011) Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 140(2):478\u2013487","journal-title":"Gastroenterology"},{"issue":"6","key":"9383_CR6","doi-asserted-by":"crossref","first-page":"G675","DOI":"10.1152\/ajpgi.00152.2012","volume":"303","author":"JS Bajaj","year":"2012","unstructured":"Bajaj JS, Hylemon PB, Ridlon JM, Heuman DM, Daita K, White MB, Monteith P, Noble NA, Sikaroodi M, Gillevet PM (2012a) Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol 303(6):G675\u2013G685","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"6","key":"9383_CR7","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/hep.25947","volume":"56","author":"JS Bajaj","year":"2012","unstructured":"Bajaj JS, O\u2019Leary JG, Reddy KR, Wong F, Olson JC, Subramanian RM, Brown G, Noble NA, Thacker LR, Kamath PS (2012b) Second infections independently increase mortality in hospitalized patients with cirrhosis: the north american consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology 56(6):2328\u20132335","journal-title":"Hepatology"},{"issue":"4","key":"9383_CR8","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/hep.25507","volume":"55","author":"JS Bajaj","year":"2012","unstructured":"Bajaj JS, Pinkerton SD, Sanyal AJ, Heuman DM (2012c) Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. Hepatology 55(4):1164\u20131171","journal-title":"Hepatology"},{"issue":"12","key":"9383_CR9","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","volume":"362","author":"NM Bass","year":"2010","unstructured":"Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP (2010) Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362(12):1071\u20131081","journal-title":"N Engl J Med"},{"key":"9383_CR10","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1111\/j.1572-0241.2001.03964.x","volume":"96","author":"AT Blei","year":"2001","unstructured":"Blei AT, Cordoba J (2001) Hepatic encephalopathy. Am J Gastroenterol 96:1968\u20131976","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"9383_CR11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1179\/joc.2002.14.3.290","volume":"14","author":"P Brigidi","year":"2012","unstructured":"Brigidi P, Swennen E, Rizzello F, Bozzolasco M, Matteuzzi D (2012) Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J Chemother 14(3):290\u2013295","journal-title":"J Chemother"},{"key":"9383_CR12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1185\/03007999309111539","volume":"13","author":"L Bucci","year":"1993","unstructured":"Bucci L, Palmieri GC (1993) Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 13:109\u2013118","journal-title":"Curr Med Res Opin"},{"issue":"4 Pt 1","key":"9383_CR13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0016-5085(77)80135-2","volume":"72","author":"HO Conn","year":"1977","unstructured":"Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff L, Levy LL (1977) Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 72(4 Pt 1):573\u2013583","journal-title":"Gastroenterology"},{"issue":"1","key":"9383_CR14","first-page":"57","volume":"4","author":"G Fera","year":"1993","unstructured":"Fera G, Agostinacchio F, Nigro M, Schiraldi O, Ferrieri A (1993) Rifaximin in the treatment of hepatic encephalopathy. Eur J Clin Res 4(1):57\u201366","journal-title":"Eur J Clin Res"},{"issue":"5","key":"9383_CR15","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/hep.25532","volume":"55","author":"J Fern\u00e1ndez","year":"2012","unstructured":"Fern\u00e1ndez J, Acevedo J, Castro M, Garcia O, de Lope CR, Roca D, Pavesi M, Sola E, Moreira L, Silva A, Seva-Pereira T, Corradi F, Mensa J, Gin\u00e8s P, Arroyo V (2012) Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 55(5):1551\u20131561","journal-title":"Hepatology"},{"issue":"5","key":"9383_CR16","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0011-393X(05)80681-2","volume":"54","author":"D Festi","year":"1993","unstructured":"Festi D, Mazzella G, Orsini M, Scottili S, Sangermano A, Li Bassi S, Ferrieri A, Falcucci M, Grossi L, Marzio L, Roda E (1993) Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety. Curr Ther Res 54(5):598\u2013609","journal-title":"Curr Ther Res"},{"issue":"6","key":"9383_CR17","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1002\/hep.23264","volume":"50","author":"T Gustot","year":"2009","unstructured":"Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R (2009) Severe Sepsis in cirrhosis. Hepatology 50(6):2022\u20132033","journal-title":"Hepatology"},{"key":"9383_CR18","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.1365-2036.2007.03464.x","volume":"26","author":"E Huang","year":"2007","unstructured":"Huang E, Esrailian E, Spiegel BMR (2007) The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy: a decision analysis. Aliment Pharmacol Ther 26:1147\u20131161","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"9383_CR19","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jhep.2010.05.002","volume":"53","author":"R Jalan","year":"2010","unstructured":"Jalan R (2010) Rifaximin in hepatic encephalopathy: more than just a non-absorable antibiotic? J Hepatol 53(3):580\u2013582","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"9383_CR20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000081991","volume":"51","author":"ZD Jiang","year":"2005","unstructured":"Jiang ZD, DuPont HL (2005) Rifaximin: in vitro and in vivo antibacterial activity\u2013a review. Chemotherapy 51(Suppl 1):67\u201372","journal-title":"Chemotherapy"},{"issue":"7","key":"9383_CR21","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.cgh.2012.02.025","volume":"10","author":"GN Kalambokis","year":"2012","unstructured":"Kalambokis GN, Mouzaki A, Rodi M, Pappas K, Fotopoulos A, Xourgia X, Tsiansos EV (2012) Rifaximin improves systemic hemodynamics and renal function in patients with alchol-related cirrhosis and ascites. Clin Gastroenterol Hepatol 10(7):815\u2013818","journal-title":"Clin Gastroenterol Hepatol"},{"key":"9383_CR22","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10620-006-9442-4","volume":"52","author":"CB Leevy","year":"2007","unstructured":"Leevy CB, Phillips JA (2007) Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 52:737\u2013741","journal-title":"Dig Dis Sci"},{"issue":"1","key":"9383_CR23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3109\/00365528708991867","volume":"22","author":"S Loft","year":"1987","unstructured":"Loft S, Sonne J, Dossing M, Andreasen PB (1987) Metronidazole pharmacokinetics in patients with hepatic encephalopathy. Scand J Gastroenterol 22(1):117\u2013123","journal-title":"Scand J Gastroenterol"},{"issue":"10","key":"9383_CR24","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1016\/j.transproceed.2010.09.173","volume":"42","author":"PS Mantry","year":"2010","unstructured":"Mantry PS, Munsaf S (2010) Rifaximin for the treatment of hepatic encephalopathy. Transplant Proc 42(10):4543\u20134547","journal-title":"Transplant Proc"},{"key":"9383_CR25","first-page":"668","volume":"36","author":"F Marco","year":"1984","unstructured":"Marco F, Amato PS, D\u2019Arienzo A (1984) Rifaximin in collateral treatment of portal-systemic encephalopathy: a preliminary report. Curr Ther Res 36:668\u2013674","journal-title":"Curr Ther Res"},{"issue":"1","key":"9383_CR26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0168-8278(02)00350-1","volume":"38","author":"A Mas","year":"2003","unstructured":"Mas A, Rod\u00e9s J, Sunyer L, Rodrigo L, Planas R, Vargas V, Castells L, Rodr\u00edguez-Mart\u00ednez D, Fern\u00e1ndez-Rodr\u00edguez C, Coll I, Pardo A (2003) Spanish Association for the Study of the Liver Hepatic Encephalopathy Cooperative Group. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 38(1):51\u201358","journal-title":"J Hepatol"},{"key":"9383_CR27","unstructured":"Massa P, Vallerino E, Dodero M (1993) Treatment of hepatic encephalopathy with rifaximin: double-blind, double-dummy study versus lactulose. Eur J Clin Res 4:7\u201318"},{"issue":"1","key":"9383_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/gut.23.1.1","volume":"23","author":"MH Morgan","year":"1982","unstructured":"Morgan MH, Read AE, Speller DC (1982) Treatment of hepatic encephalopathy with metronidazole. Gut 23(1):1\u20137","journal-title":"Gut"},{"issue":"10","key":"9383_CR29","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1016\/j.transproceed.2007.09.031","volume":"39","author":"GW Neff","year":"2007","unstructured":"Neff GW, Kemmer N, Kaiser T, Zacharias V, Majoras N, Safdar K (2007) Outcomes in adult and pediatric liver transplantation among various ethnic groups. Transplant Proc 39(10):3204\u20133206","journal-title":"Transplant Proc"},{"issue":"2","key":"9383_CR30","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/MCG.0b013e318231faae","volume":"46","author":"GW Neff","year":"2012","unstructured":"Neff GW, Jones M, Broda T, Jonas M, Ravi R, Novick D, Kaiser TE, Kemmer N (2012) Durability of rifaximin response in hepatic encephalopathy. J Clin Gastroenterol 46(2):168\u2013171","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"9383_CR31","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/BF01308097","volume":"26","author":"F Orlandi","year":"1981","unstructured":"Orlandi F, Freddara U, Candelaresi MT, Morettini A, Corazza GR, Di Simone A, Dobrilla G, Cavallini G (1981) Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: a randomized clinical study. Dig Dis Sci 26(6):498\u2013506","journal-title":"Dig Dis Sci"},{"issue":"3","key":"9383_CR32","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3349\/ymj.2005.46.3.399","volume":"46","author":"YH Paik","year":"2005","unstructured":"Paik YH, Lee KS, Han KH, Song KH, Kim MH, Moon BS, Ahn SH, Lee SJ, Park HJ, Lee DK, Chon CY, Lee SI, Moon YM (2005) Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J 46(3):399\u2013407","journal-title":"Yonsei Med J"},{"key":"9383_CR33","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0011-393X(05)80433-3","volume":"52","author":"P Parini","year":"1992","unstructured":"Parini P, Cipolla A, Ronci M, Antionio M, Salzetta A, Mazzella G, Roda E (1992) Effect of paromomycin in the treatment of portal-systemic encephalopathy. Curr Ther Res 52:34","journal-title":"Curr Ther Res"},{"key":"9383_CR34","first-page":"480309","volume":"2012","author":"Z Poh","year":"2012","unstructured":"Poh Z, Chang PE (2012) A current review of the diagnostic and treatment strategies of hepatic encephalopathy. Int J Hepatol 2012:480309","journal-title":"Int J Hepatol"},{"key":"9383_CR35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1746-6342.2006.03215.x","volume":"1","author":"FF Poordad","year":"2007","unstructured":"Poordad FF (2007) Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther 1:3\u20139","journal-title":"Aliment Pharmacol Ther"},{"key":"9383_CR36","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrgastro.2010.116","volume":"7","author":"R Prakash","year":"2010","unstructured":"Prakash R, Mullen KD (2010) Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 7:515\u2013525","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"9383_CR37","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1038\/ajg.2009.738","volume":"105","author":"O Riggio","year":"2010","unstructured":"Riggio O, Mannaioni G, Ridola L, Angeloni S, Merli M, Carl\u00e0 V, Salvatori FM, Moroni F (2010) Peripheral and splanchnic indole and oxindole levels in cirrhotic patients: a study on the pathophysiology of hepatic encephalopathy. Am J Gastroenterol 105(6):1374\u20131381","journal-title":"Am J Gastroenterol"},{"key":"9383_CR38","doi-asserted-by":"crossref","unstructured":"Sanyal A, Bass N, Poorad F, Sheikh MY, Mullen K, Sigal S, Frederick T, Brown, Jr R, Bhandari B, Sedghi S, Merchant K, Huang S, Shaw A, Bortey E, Forbes W (2010) Rifaximin decreases venous ammonia concentrations and time-weighted average ammonia concentrations correlate with overt hepatic encephalopathy (HE) as assessed by Conn Score in a 6-months study. Program and abstracts of the 45th Annual Meeting of the European Association for the Study of the Liver Abstract 195","DOI":"10.1016\/S0168-8278(10)60197-3"},{"issue":"8","key":"9383_CR39","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2036.2011.04808.x","volume":"34","author":"A Sanyal","year":"2011","unstructured":"Sanyal A, Younossi ZM, Bass NM, Mullen KD, Poordad F, Brown RS, Vemuru RP, Mazen Jamal M, Huang S, Merchant K, Bortey E, Forbes WP (2011) Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy \u2013 a double-blind placebo-controlled study. Aliment Pharmacol Ther 34(8):853\u2013861","journal-title":"Aliment Pharmacol Ther"},{"key":"9383_CR40","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.jhep.2010.07.045","volume":"54","author":"DL Shawcross","year":"2011","unstructured":"Shawcross DL, Sharifi Y, Canavan JB, Yeoman AD, Abeles RD, Taylor NJ, Auzinger G, Bernal W, Wendon JA (2011) Infection and systemic inflammation, not ammonia, are associated with Grade 3\/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol 54:640\u2013649","journal-title":"J Hepatol"},{"issue":"2","key":"9383_CR41","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/ajg.2010.455","volume":"106","author":"SS Sidhu","year":"2011","unstructured":"Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK (2011) Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol 106(2):307\u2013316","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"9383_CR42","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.cgh.2012.05.016","volume":"10","author":"M Stepanova","year":"2012","unstructured":"Stepanova M, Mishra A, Venkatesan C, Younossi ZM (2012) In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin Gastroenterol Hepatol 10(9):1034\u20131041","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"9383_CR43","first-page":"542","volume":"39","author":"E Strauss","year":"1992","unstructured":"Strauss E, Tramote R, Silva EP, Caly WR, Honain NZ, Maffei RA, de S\u00e1 MF (1992) Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 39(6):542\u2013545","journal-title":"Hepatogastroenterology"},{"issue":"6","key":"9383_CR44","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/gut.31.6.702","volume":"31","author":"K Tarao","year":"1990","unstructured":"Tarao K, Ikeda T, Hayashi K, Sakurai A, Okada T, Ito T, Karube H, Nomoto T, Mizuno T, Shindo K (1990) Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy. Gut 31(6):702\u2013706","journal-title":"Gut"},{"issue":"6","key":"9383_CR45","first-page":"387","volume":"11","author":"R Testa","year":"1985","unstructured":"Testa R, Eftimiadi C, Sukkar GS, De Leo C, Rovida S, Schito GC, Celle G (1985) Drugs Exp Clin Res 11(6):387\u2013392","journal-title":"Drugs Exp Clin Res"},{"key":"9383_CR46","unstructured":"U.S. Food and Drug Administration (2010) Briefing Document for Gastrointestinal Drugs Advisory Committee Meeting 23 February 2010. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/GastrointestinalDrugsAdvisoryCommittee\/UCM201081.pdf . Accessed 3 December 2012"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-013-9383-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11011-013-9383-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-013-9383-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:20:19Z","timestamp":1595377219000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11011-013-9383-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,8]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["9383"],"URL":"https:\/\/doi.org\/10.1007\/s11011-013-9383-5","relation":{},"ISSN":["0885-7490","1573-7365"],"issn-type":[{"value":"0885-7490","type":"print"},{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,8]]}}}